Regend Therapeutics is a leading biopharmaceutical company that was established in 2015 by a team of renowned experts in the field of regenerative medicine. With a mission to rebuild life and reshape health, the company focuses on the field of human organ regeneration using precursor cells. Regend Therapeutics develops innovative cell and gene therapy products to repair, regenerate, and enhance human tissues and organs, addressing clinical needs that traditional treatment methods cannot meet.

The company covers the entire spectrum of regenerative medicine, from basic research and preclinical development to clinical trials and commercial production. It has established state-of-the-art research and development facilities in Suzhou, Shanghai, and Zhejiang, as well as a production and storage base in Nanchang. Regend Therapeutics has also formed strategic partnerships with leading biopharmaceutical companies such as Haier Bio, Olympus, Boehringer Ingelheim, and Tasly Group.

The company's flagship technology, the R-Clone technique, is internationally recognized and has been published in prestigious journals such as Nature, Cell, and Protein&Cell. Leveraging this technology, Regend Therapeutics has developed a pipeline of products targeting various respiratory diseases, diabetes-related kidney disease, and kidney transplantation repair. Notably, Regend Therapeutics' self-developed precursor cell therapy, REGEND001, is the first domestically produced regenerative medicine product for lung regeneration.

It has received clinical trial approvals from the National Medical Products Administration for the treatment of idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) with impaired pulmonary diffusion. With its strong scientific research capabilities, Regend Therapeutics collaborates with top research institutions and medical organizations globally to establish an integrated alliance that encompasses research, clinical trials, industrialization, and sales. The company aims to become a leading research and development center, a hub for technology transfer and industrialization, and a talent base in the field of regenerative medicine, driving the next generation of medical revolution centered around regenerative medicine